STERIS plc
NYSE:STE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
197.44
247.17
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one STE stock under the Base Case scenario is 224.78 USD. Compared to the current market price of 214.34 USD, STERIS plc is Undervalued by 5%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
STERIS plc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for STE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
STERRIS plc is a globally recognized leader in the field of infection prevention, surgical, and critical care solutions, committed to enhancing patient safety and healthcare efficiency. With a rich history spanning over 100 years, the company operates in more than 60 countries, offering a diverse range of products and services tailored to meet the needs of healthcare providers. STERIS’s innovative technologies, including sterilization and disinfection equipment, surgical tables, and integrated surgical suites, position it as a vital partner for hospitals and medical facilities striving to uphold high standards of patient care. This focus on innovation not only drives customer loyalty but als...
STERRIS plc is a globally recognized leader in the field of infection prevention, surgical, and critical care solutions, committed to enhancing patient safety and healthcare efficiency. With a rich history spanning over 100 years, the company operates in more than 60 countries, offering a diverse range of products and services tailored to meet the needs of healthcare providers. STERIS’s innovative technologies, including sterilization and disinfection equipment, surgical tables, and integrated surgical suites, position it as a vital partner for hospitals and medical facilities striving to uphold high standards of patient care. This focus on innovation not only drives customer loyalty but also positions the company favorably in an industry that increasingly prioritizes safety and efficiency.
For investors, STERIS presents a robust growth trajectory, bolstered by a strategic approach to acquisitions and an expansion into emerging markets. The company has consistently delivered strong financial results, reflecting resilience even amidst industry challenges. With an ongoing commitment to research and development, STERIS is well-positioned to leverage trends in healthcare modernization and increasing demand for infection control solutions. As global healthcare systems adapt to rising patient care standards and regulatory requirements, STERIS’s established reputation and forward-thinking strategies make it an attractive investment opportunity for those looking to capitalize on the evolving landscape of healthcare services.
STERIS plc operates in the healthcare and pharmaceutical sectors, providing essential products and services focused on sterilization and decontamination. The company’s core business segments are:
-
Healthcare Products:
- This segment includes a wide range of products used in the healthcare industry to ensure the safety and efficacy of surgical procedures. This includes sterilizers, disinfectants, surgical instruments, and accessories used in hospitals and surgery centers.
-
Medical Device and Pharmaceutical Services:
- STERIS provides sterilization services for medical devices and pharmaceuticals, ensuring compliance with regulatory standards. This segment also includes consulting services to help companies with product development and regulatory compliance.
-
Life Sciences:
- The Life Sciences segment focuses on serving the biopharmaceutical and laboratory markets. STERIS offers solutions related to sterilization, cleaning, and contamination control specifically designed for the production of drugs and vaccines.
-
Infection Prevention:
- This segment involves products and services aimed at preventing infections in healthcare settings. This can include a range of consumables, cleaning products, and education/training services for healthcare professionals.
-
Other Services:
- STERIS also offers a variety of support services, such as installation and maintenance of equipment, as well as consulting and training services to enhance operational efficiency in healthcare settings.
These segments illustrate STERIS's commitment to enhancing patient safety and operational efficiency across healthcare and pharmaceutical industries, positioning the company as a leader in infection prevention and sterilization solutions.
STERIS plc possesses several unique competitive advantages that set it apart from its rivals in the healthcare and life sciences sectors:
-
Comprehensive Product Portfolio: STERIS offers a wide range of products and services, including sterilization, disinfection, and surgical support services. This diversity allows the company to cater to various needs within the healthcare industry, providing one-stop solutions that many competitors may not offer.
-
Strong Focus on Innovation: STERIS invests significantly in research and development, leading to innovative solutions in infection prevention, sterilization technologies, and surgical instruments. This focus on innovation helps maintain a technological edge over competitors.
-
High Barriers to Entry: The healthcare and sterilization markets are heavily regulated, requiring substantial capital investment and expertise to enter. STERIS’s established reputation and compliance with regulatory standards create a significant barrier for new entrants.
-
Brand Trust and Reputation: With decades of experience in the industry, STERIS has built a strong brand recognized for quality and reliability. This reputational strength fosters customer loyalty and can be a critical deciding factor for healthcare providers when selecting suppliers.
-
Global Reach with Local Expertise: STERIS has a broad international presence, enabling it to serve customers across various markets while adapting its services to meet local regulations and customer preferences. This global footprint combined with local expertise enhances its competitive position.
-
Strong Customer Relationships: STERIS has cultivated long-term partnerships with healthcare institutions and professionals, which not only enhances customer retention but also drives repeat business and word-of-mouth referrals.
-
Strategic Acquisitions: The company has a history of strategic acquisitions that enhance its capabilities, expand its product offerings, and improve its market positioning. Such acquisitions can provide quick access to new technologies or market segments.
-
High-Quality Customer Support and Services: STERIS emphasizes delivering exceptional customer service, including training, implementation, and support. This commitment to service can differentiate it from competitors that may focus solely on product sales.
-
Emphasis on Sustainability: Increasingly, hospitals and healthcare providers are prioritizing sustainability. STERIS has initiatives aimed at reducing environmental impact, which can appeal to clients looking to enhance their own sustainability practices.
-
Robust Supply Chain Management: The company maintains control over critical components of its supply chain, ensuring quality and reliability in its product offerings. Efficient supply chain practices help reduce costs and improve service delivery times.
By leveraging these competitive advantages, STERIS plc strengthens its position in the market, enabling it to navigate challenges and capitalize on growth opportunities within the healthcare and life sciences sectors.
STERIS plc, a leading provider of infection prevention and other procedural products and services, faces several risks and challenges in the near future:
-
Regulatory Compliance: As a global healthcare company, STERIS must comply with stringent regulations regarding medical devices and pharmaceutical products. Changes in regulations or failure to comply can result in penalties and impact market access.
-
Market Competition: The healthcare industry is highly competitive, with numerous players offering similar products and services. STERIS faces pressure from established competitors and emerging startups, which could affect its market share and profitability.
-
Technological Advancements: Rapid advancements in medical and sterilization technology may require STERIS to continuously innovate and invest in research and development. Failure to keep up could result in obsolescence.
-
Supply Chain Disruptions: Global supply chains have been affected by various factors, such as geopolitical tensions, natural disasters, and pandemics. Disruptions could affect STERIS’s ability to manufacture and deliver products on time.
-
Economic Fluctuations: Economic downturns or changes in healthcare spending can impact demand for STERIS’s products and services. Budget constraints faced by hospitals and healthcare providers could lead to reduced orders.
-
Litigation and Liability Risks: As with any medical device company, STERIS may face litigation risks related to product liability claims. Adverse outcomes in legal disputes could impact the company's reputation and financial stability.
-
Cybersecurity Threats: The increasing digitization of healthcare presents heightened risks of data breaches and cyberattacks. Protecting sensitive patient and operational data is critical to maintaining trust and compliance.
-
Global Economic Uncertainty: Economic uncertainties, such as inflation and recession, could impact healthcare budgets and the willingness of facilities to make capital expenditures on STERIS products.
-
Changes in Healthcare Policy: Legislative changes in healthcare policy, especially in major markets like the U.S. and EU, can impact reimbursement rates, pricing strategies, and overall demand for STERIS’s offerings.
-
Talent Acquisition and Retention: Attracting and retaining skilled professionals in a competitive labor market remains a challenge. A skilled workforce is essential for innovation and maintaining operational efficiency.
By proactively addressing these risks and challenges, STERIS can position itself to navigate future uncertainties effectively.
Revenue & Expenses Breakdown
STERIS plc
Balance Sheet Decomposition
STERIS plc
Current Assets | 1.9B |
Cash & Short-Term Investments | 172.2m |
Receivables | 923.3m |
Other Current Assets | 842.3m |
Non-Current Assets | 8.3B |
PP&E | 2.1B |
Intangibles | 6.2B |
Other Non-Current Assets | 60.3m |
Current Liabilities | 805.5m |
Accounts Payable | 235.1m |
Accrued Liabilities | 353.7m |
Other Current Liabilities | 216.7m |
Non-Current Liabilities | 2.8B |
Long-Term Debt | 2.2B |
Other Non-Current Liabilities | 687m |
Earnings Waterfall
STERIS plc
Revenue
|
5.1B
USD
|
Cost of Revenue
|
-2.9B
USD
|
Gross Profit
|
2.2B
USD
|
Operating Expenses
|
-1.3B
USD
|
Operating Income
|
933.4m
USD
|
Other Expenses
|
-498.6m
USD
|
Net Income
|
434.8m
USD
|
Free Cash Flow Analysis
STERIS plc
USD | |
Free Cash Flow | USD |
In its second quarter, STERIS reported a 7% increase in total revenue, maintaining momentum from the fiscal year start. However, gross margins dipped to 43.7%, partly due to labor inflation and productivity challenges, leading to an EBIT margin of 22.2%. Looking ahead, STERIS expects 6% to 7% constant currency organic revenue growth and adjusted earnings per share between $9.05 and $9.25 for the fiscal year. Healthcare revenue is projected to grow mid- to high single digits, despite capital equipment sales expected to remain flat, while AST anticipates high single-digit growth. STERIS also aims for free cash flow around $700 million, with capital expenditures at approximately $360 million.
What is Earnings Call?
STE Profitability Score
Profitability Due Diligence
STERIS plc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
STERIS plc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
STE Solvency Score
Solvency Due Diligence
STERIS plc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
STERIS plc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STE Price Targets Summary
STERIS plc
According to Wall Street analysts, the average 1-year price target for STE is 257.06 USD with a low forecast of 232.3 USD and a high forecast of 278.25 USD.
Dividends
Current shareholder yield for STE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
STE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
STERIS Plc engages in the provision of healthcare and life science product and service solutions. The firm offers a mix of consumable products, such as detergents, gastrointestinal (GI) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair solutions, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (OR) integration. The firm operates through four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Its Healthcare segment focused on sterile processing departments and procedural centers, such as operating rooms, endoscopy suites, and renal dialysis centers.
Contact
IPO
Employees
Officers
The intrinsic value of one STE stock under the Base Case scenario is 224.78 USD.
Compared to the current market price of 214.34 USD, STERIS plc is Undervalued by 5%.